Harmonet (Ethinylestradiol, Gestodene)

Harmonet is prescribed primarily for the prevention of unintended pregnancy in women of reproductive age.

• Primary use as a combined hormonal contraceptive taken once daily for 21 consecutive days followed by a hormone‑free interval.
• Regulation of menstrual cycle timing and reduction of menstrual flow when used continuously.
• Management of moderate acne associated with androgen excess, as an off‑label therapeutic option in some jurisdictions.
• Potential benefit in reducing the risk of ovarian cyst formation during long‑term use.
• Adjunctive therapy for endometriosis symptom control under physician supervision.

Like all combined oral contraceptives, Harmonet may cause a range of side effects, most of which are mild and transient.

Common

• Nausea or mild stomach upset.
• Breast tenderness or enlargement.
• Headache or mild migraine.
• Irregular vaginal bleeding or spotting between periods.
• Weight fluctuations due to fluid retention.

Serious

• Deep vein thrombosis or pulmonary embolism.
• Severe hypertension or stroke.

Before starting Harmonet, women should discuss their medical history with a healthcare professional to ensure safe use.

• Contraindicated in women who are pregnant, have a history of thromboembolic disorders, or known estrogen‑dependent tumors.
• Avoid use in smokers over 35 years of age due to increased cardiovascular risk.
• Screen for hypertension, diabetes, liver disease, or migraine with aura prior to prescribing.
• Inform the prescriber of any recent major surgery or prolonged immobilization.
• Use an additional barrier method during the first 7 days of treatment.
• Regularly monitor blood pressure and lipid profile during long‑term therapy.

Harmonet can interact with several medications, affecting its efficacy or increasing the risk of adverse events.

Avoid

• Antibiotics such as rifampin or griseofulvin that induce hepatic enzymes and reduce contraceptive effectiveness.
• Anticonvulsants like carbamazepine, phenytoin, or phenobarbital that increase hormone metabolism.
• Antiretroviral drugs (e.g., efavirenz) that lower plasma levels of ethinylestradiol.
• St. John’s wort, a herbal CYP3A4 inducer, which may diminish contraceptive protection.

Use with caution

• Antifungal agents (e.g., ketoconazole) that inhibit CYP3A4 and may increase hormone levels.
• Selective serotonin reuptake inhibitors (SSRIs) that can affect bleeding risk.
• Diuretics that may alter fluid balance and blood pressure.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can increase cardiovascular risk when combined with estrogen.